Life sciences group Thermo Fisher agrees to acquire PE-owned drug trial software maker Clario for $9.4B in an all-cash deal expected to close by mid-2026

ft.com/content/2d12fd44-dd56-4c77-a9b8-ca20c277bb66?accessToken=zwAGQljyyyIQkc8tEv1E3VZMd9OpuMogwne7Zg.MEUCIQCZ4SEfde62tM9mygGcJ790QtskBwkv5v5bfU3xAnBn-AIgSbj21inWsJouZBoljwmCcF3wI8-NaUOu9M0Th1s5KkQ&sharetype=gift

This story appeared on ft.com, 2025-10-30 04:13:48.747000.
The Entire Business World on a Single Page. Free to Use →